New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 4, 2012
06:38 EDTJAZZCorrection: Jazz Pharmaceuticals initiates Erwinaze trial, says Brean Capital
Jazz announced initiated its new clinical trial for Erwinaze with will evaluate intravenous administration in patients with ALL as an alternative to intramuscular injection. Brean Murray maintains its estimates but believes there could be upside to its 2014 forecast. Shares are Buy rated with an $81 price target.
News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 17, 2014
07:53 EDTJAZZJazz Pharmaceuticals shares 'signifincantly undervalued,' says FBR Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use